secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001193125-25-225858
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics files routine corporate presentation update; no material new disclosure
--------------------------------------------------------------------------------

- Presentation shows [212Pb]VMT-α-NET Phase 1/2a data in NET with confirmed partial response in patient 103-105.
- Tolerability data: mild, transient creatinine increase; no unexpected safety signals.
- Pipeline includes [212Pb]VMT01 for melanoma and [212Pb]PSV359 targeting FAP-α in trials.
- Pre-targeting platform and supply chain manufacturing infrastructure also highlighted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312525225858/0001193125-25-225858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312525225858/catx-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-225858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer